We Claim:

1. Use of an antibody specific for CD19 wherein said antibody comprises an HCDR1 region comprising sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising sequence MQHLEYPIT (SEQ ID NO: 6) in the manufacture of a medicament for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia, wherein the antibody specific for CD19 is used in combination with venetoclax.

2. The use according to claim 1, wherein the antibody has ADCC activity.

3. The use according to claim 1 or claim 2, wherein the antibody comprises a variable heavy chain comprising the sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYW G QGTLVTVSS (SEQ ID NO: 10) and a variable light chain comprising the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

4. The use according to any one of the preceding claims, wherein the antibody comprises a heavy chain constant domain comprising the sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE LLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP REEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).

5. The use according to any one of the preceding claims, wherein the antibody comprises a light chain constant domain comprising the sequence

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).

6. The use according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are formulated in different pharmaceutical compositions.

7. The use according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are to be administered separately.

8. The use according to any one of the preceding claims, wherein:

(a) venetoclax is to be administered prior to administration of the antibody specific for CD19; or

(b) said antibody specific for CD19 is to be administered prior to venetoclax.

9. The use according to any one of claims 1 to 6, wherein said antibody specific for CD19 and venetoclax are to be administered simultaneously.

10. The use according to any one of the preceding claims, wherein said antibody specific for CD19 and venetoclax are to be administered at a time where both drugs are active in the patient at the same time.

11. The use according to any one of the preceding claims, in the manufacture of a medicament for the treatment of chronic lymphocytic leukemia.

12. The use according to any one of claims 1 to 10, in the manufacture of a medicament for the treatment of acute lymphoblastic leukemia.

13. The use according to any one of claims 1 to 10, in the manufacture of a medicament for the treatment of non-Hodgkin’s lymphoma.

14. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is follicular lymphoma.

15. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is small lymphocytic lymphoma.

16. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is mucosa-associated lymphoid tissue lymphoma.

17. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is marginal zone lymphoma.

18. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is diffuse large B cell lymphoma.

19. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is Burkitt's lymphoma.

20. The use according to claim 13, wherein the non-Hodgkin’s lymphoma is mantle cell lymphoma.